SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Mikati MA, El Hokayem JA, El Sabban ME. Effects of a single dose of erythropoietin on subsequent seizure susceptibility in rats exposed to acute hypoxia at P10. Epilepsia 2007; 48: 175181.
  • 2
    Chong ZZ, Kang JQ, Maiese K. Angiogenesis and plasticity: Role of erythropoietin in vascular systems. J. Hematother. Stem Cell Res. 2002; 11: 863871.
  • 3
    Chong ZZ, Kang JQ, Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation 2002; 106: 29732979.
  • 4
    Chong ZZ, Kang JQ, Maiese K. Hematopoietic factor erythropoietin fosters neuroprotection through novel signal transduction cascades. J. Cereb. Blood Flow Metab. 2002; 22: 503514.
  • 5
    Chong ZZ, Kang JQ, Maiese K. Erythropoietin: Cytoprotection in vascular and neuronal cells. Curr. Drug Targets Cardiovasc. Haematol. Disord. 2003; 3: 141154.
  • 6
    Chong ZZ, Kang JQ, Maiese K. Erythropoietin fosters both intrinsic and extrinsic neuronal protection through modulation of microglia, Akt1, Bad, and caspase-mediated pathways. Br. J. Pharmacol. 2003; 138: 11071118.
  • 7
    Chong ZZ, Kang JQ, Maiese K. Apaf-1, Bcl-xL, cytochrome c, and caspase-9 form the critical elements for cerebral vascular protection by erythropoietin. J. Cereb. Blood Flow Metab. 2003; 23: 320330.
  • 8
    Chong ZZ, Maiese K. Erythropoietin involves the phosphatidylinositol 3-kinase pathway, 14-3-3 protein and FOXO3a nuclear trafficking to preserve endothelial cell integrity. Br. J. Pharmacol. 2007; 150: 839850.
  • 9
    Moon C, Krawczyk M, Lakatta EG, Talan MI. Therapeutic effectiveness of a single vs multiple doses of erythropoietin after experimental myocardial infarction in rats. Cardiovasc. Drugs Ther. 2006; 20: 245251.
  • 10
    Moon C, Krawczyk M, Paik D et al. Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties. J. Pharmacol. Exp. Ther. 2006; 316: 9991005.
  • 11
    Maiese K, Chong ZZ, Li F, Shang YC. Erythropoietin: Elucidating new cellular targets that broaden therapeutic strategies. Prog. Neurobiol. 2008; 85: 194213.
  • 12
    Li F, Chong ZZ, Maiese K. Erythropoietin on a tightrope: Balancing neuronal and vascular protection between intrinsic and extrinsic pathways. Neurosignals 2004; 13: 265289.
  • 13
    Tan CC, Eckardt KU, Firth JD, Ratcliffe PJ. Feedback modulation of renal and hepatic erythropoietin mRNA in response to graded anemia and hypoxia. Am. J. Physiol. 1992; 263: F474F481.
  • 14
    Bazan JF. A novel family of growth factor receptors: A common binding domain in the growth hormone, prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor beta-chain. Biochem. Biophys. Res. Commun. 1989; 164: 788795.
  • 15
    Watowich SS, Hilton DJ, Lodish HF. Activation and inhibition of erythropoietin receptor function: Role of receptor dimerization. Mol. Cell. Biol. 1994; 14: 35353549.
  • 16
    Koshimura K, Murakami Y, Sohmiya M, Tanaka J, Kato Y. Effects of erythropoietin on neuronal activity. J. Neurochem. 1999; 72: 25652572.
  • 17
    Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA 2005; 293: 9095.
  • 18
    Genc S, Koroglu TF, Genc K. Erythropoietin and the nervous system. Brain Res. 2004; 1000: 1931.
  • 19
    Maiese K, Hou J, Chong ZZ, Shang YC. Erythropoietin, forkhead proteins, and oxidative injury: Biomarkers and biology. Sci. World J. 2009; 9: 10721104.
  • 20
    Maiese K, Li F, Chong ZZ. Erythropoietin in the brain: Can the promise to protect be fulfilled? Trends Pharmacol. Sci. 2004; 25: 577583.
  • 21
    Kawakami M, Sekiguchi M, Sato K, Kozaki S, Takahashi M. Erythropoietin receptor-mediated inhibition of exocytotic glutamate release confers neuroprotection during chemical ischemia. J. Biol. Chem. 2001; 276: 39 46939 475.
  • 22
    Blondeau N, Plamondon H, Richelme C, Heurteaux C, Lazdunski M. K(ATP) channel openers, adenosine agonists and epileptic preconditioning are stress signals inducing hippocampal neuroprotection. Neuroscience 2000; 100: 465474.
  • 23
    Siren AL, Fratelli M, Brines M et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc. Natl Acad. Sci. USA 2001; 98: 40444049.
  • 24
    Genc S, Koroglu TF, Genc K. Erythropoietin as a novel neuroprotectant. Restor. Neurol. Neurosci. 2004; 22: 105119.
  • 25
    Muller N, Riedel M, Hadjamu M, Schwarz MJ, Ackenheil M, Gruber R. Increase in expression of adhesion molecule receptors on T helper cells during antipsychotic treatment and relationship to blood-brain barrier permeability in schizophrenia. Am. J. Psychiatry 1999; 156: 634636.
  • 26
    Meyer U, Feldon J, Dammann O. Schizophrenia and autism: Both shared and disorder-specific pathogenesis via perinatal inflammation? Pediatr. Res. 2011; 69: 26R33R.
  • 27
    Saetre P, Emilsson L, Axelsson E, Kreuger J, Lindholm E, Jazin E. Inflammation-related genes up-regulated in schizophrenia brains. BMC Psychiatry 2007; 7: 46.
  • 28
    Baker I, Masserano J, Wyatt RJ. Serum cytokine concentrations in patients with schizophrenia. Schizophr. Res. 1996; 20: 199203.
  • 29
    Watanabe Y, Someya T, Nawa H. Cytokine hypothesis of schizophrenia pathogenesis: Evidence from human studies and animal models. Psychiatry Clin. Neurosci. 2011; 64: 217230.
  • 30
    Brines M, Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat. Rev. Neurosci. 2005; 6: 484494.
  • 31
    de Klerk OL, Willemsen AT, Bosker FJ et al. Regional increase in P-glycoprotein function in the blood-brain barrier of patients with chronic schizophrenia: A PET study with [(11)C]verapamil as a probe for P-glycoprotein function. Psychiatry Res. 2010; 183: 151156.
  • 32
    Bitanihirwe BK, Woo TU. Oxidative stress in schizophrenia: An integrated approach. Neurosci. Biobehav. Rev. 2011; 35: 878893.
  • 33
    Zhang M, Zhao Z, He L, Wan C. A meta-analysis of oxidative stress markers in schizophrenia. Sci. China Life Sci. 2011; 53: 112124.
  • 34
    Studer L, Csete M, Lee SH et al. Enhanced proliferation, survival, and dopaminergic differentiation of CNS precursors in lowered oxygen. J. Neurosci. 2000; 20: 73777383.
  • 35
    Lee JY, Koh HC, Chang MY, Park CH, Lee YS, Lee SH. Erythropoietin and bone morphogenetic protein 7 mediate ascorbate-induced dopaminergic differentiation from embryonic mesencephalic precursors. Neuroreport 2003; 14: 14011404.
  • 36
    Konishi Y, Chui DH, Hirose H, Kunishita T, Tabira T. Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo. Brain Res. 1993; 609: 2935.
  • 37
    Toro CT, Deakin JF. Adult neurogenesis and schizophrenia: A window on abnormal early brain development? Schizophr. Res. 2007; 90: 114.
  • 38
    Reif A, Schmitt A, Fritzen S, Lesch KP. Neurogenesis and schizophrenia: Dividing neurons in a divided mind? Eur. Arch. Psychiatry Clin. Neurosci. 2007; 257: 290299.
  • 39
    Ehrenreich H, Degner D, Meller J et al. Erythropoietin: A candidate compound for neuroprotection in schizophrenia. Mol. Psychiatry 2004; 9: 4254.
  • 40
    Lipska BK, Weinberger DR. To model a psychiatric disorder in animals: Schizophrenia as a reality test. Neuropsychopharmacology 2000; 23: 223239.
  • 41
    Lieberman J, Chakos M, Wu H et al. Longitudinal study of brain morphology in first episode schizophrenia. Biol. Psychiatry 2001; 49: 487499.
  • 42
    Bierer R, Peceny MC, Hartenberger CH, Ohls RK. Erythropoietin concentrations and neurodevelopmental outcome in preterm infants. Pediatrics 2006; 118: e635e640.
  • 43
    Peng H, Derrick BE, Martinez JL Jr. Identification of upregulated SCG10 mRNA expression associated with late-phase long-term potentiation in the rat hippocampal Schaffer-CA1 pathway in vivo. J. Neurosci. 2003; 23: 66176626.
  • 44
    Holahan M, Routtenberg A. The protein kinase C phosphorylation site on GAP-43 differentially regulates information storage. Hippocampus 2008; 18: 10991102.
  • 45
    Solomonia RO, Apkhazava D, Nozadze M, Jackson AP, McCabe BJ, Horn G. Different forms of MARCKS protein are involved in memory formation in the learning process of imprinting. Exp. Brain Res. 2008; 188: 323330.
  • 46
    Tischmeyer W, Grimm R, Schicknick H, Brysch W, Schlingensiepen KH. Sequence-specific impairment of learning by c-jun antisense oligonucleotides. Neuroreport 1994; 5: 15011504.
  • 47
    Arami S, Jucker M, Schachner M, Welzl H. The effect of continuous intraventricular infusion of L1 and NCAM antibodies on spatial learning in rats. Behav. Brain Res. 1996; 81: 8187.
  • 48
    Flashman LA, Green MF. Review of cognition and brain structure in schizophrenia: Profiles, longitudinal course, and effects of treatment. Psychiatr. Clin. North Am. 2004; 27: 118.
  • 49
    Ehrenreich H, Hinze-Selch D, Stawicki S et al. Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Mol. Psychiatry 2007; 12: 206220.
  • 50
    Randolph C. RBANS Manual: Repeatable Battery for the Assessment of Neuropsychological Status. 1998.
  • 51
    Heaton STKGIR. WCST-64: Wisconsin card sorting test-64 card version. 2000.
  • 52
    Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987; 13: 261276.
  • 53
    Naber D, Moritz S, Lambert M et al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr. Res. 2001; 50: 7988.
  • 54
    Jung E, Biehl H, Maurer K, Bauer-Shubart C. DAS-M disability assessment schedule. Beltz, Weinheim, 1989.
  • 55
    Kokhaei P, Abdalla AO, Hansson L et al. Expression of erythropoietin receptor and in vitro functional effects of epoetins in B-cell malignancies. Clin. Cancer Res. 2007; 13: 35363544.
  • 56
    Hardee ME, Rabbani ZN, Arcasoy MO et al. Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity. Mol. Cancer Ther. 2006; 5: 356361.
  • 57
    Lai SY, Grandis JR. Understanding the presence and function of erythropoietin receptors on cancer cells. J. Clin. Oncol. 2006; 24: 46754676.
  • 58
    Henke M, Laszig R, Rube C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 2003; 362: 12551260.
  • 59
    Leyland-Jones B, Semiglazov V, Pawlicki M et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J. Clin. Oncol. 2005; 23: 59605972.
  • 60
    Baoutina A, Coldham T, Bains GS, Emslie KR. Gene doping detection: Evaluation of approach for direct detection of gene transfer using erythropoietin as a model system. Gene Ther. 2007; 17: 10221032.
  • 61
    Diamanti-Kandarakis E, Konstantinopoulos PA, Papailiou J, Kandarakis SA, Andreopoulos A, Sykiotis GP. Erythropoietin abuse and erythropoietin gene doping: Detection strategies in the genomic era. Sports Med. 2005; 35: 831840.
  • 62
    Segura J, Pascual JA, Gutierrez-Gallego R. Procedures for monitoring recombinant erythropoietin and analogues in doping control. Anal. Bioanal. Chem. 2007; 388: 15211529.
  • 63
    Kanbay M, Akcay A, Delibasi T et al. Comparison of effects of darbepoetin alfa and epoetin alfa on serum endothelin level and blood pressure. Adv. Ther. 2007; 24: 346352.
  • 64
    Eliopoulos N, Gagnon RF, Francois M, Galipeau J. Erythropoietin delivery by genetically engineered bone marrow stromal cells for correction of anemia in mice with chronic renal failure. J. Am. Soc. Nephrol. 2006; 17: 15761584.
  • 65
    Orive G, De Castro M, Ponce S et al. Long-term expression of erythropoietin from myoblasts immobilized in biocompatible and neovascularized microcapsules. Mol. Ther. 2005; 12: 283289.
  • 66
    Yu YP, Xu QQ, Zhang Q, Zhang WP, Zhang LH, Wei EQ. Intranasal recombinant human erythropoietin protects rats against focal cerebral ischemia. Neurosci. Lett. 2005; 387: 510.
  • 67
    Montero M, Poulsen FR, Noraberg J et al. Comparison of neuroprotective effects of erythropoietin (EPO) and carbamylerythropoietin (CEPO) against ischemia-like oxygen-glucose deprivation (OGD) and NMDA excitotoxicity in mouse hippocampal slice cultures. Exp. Neurol. 2007; 204: 106117.
  • 68
    Erbayraktar S, Grasso G, Sfacteria A et al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc. Natl Acad. Sci. USA 2003; 100: 67416746.
  • 69
    Maiese K, Chong ZZ, Shang YC. Raves and risks for erythropoietin. Cytokine Growth Factor Rev. 2008; 19: 145155.